Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT04777851
Ignite Creation Date: 2024-05-06 @ 3:49 PM
Last Modification Date: 2024-10-26 @ 1:58 PM
Study NCT ID: NCT04777851
Protocol Section: NCT04777851
Start Identification Module Data
Expand Identification Module Data
Brief Title: Regorafenib-pembrolizumab vs TACETARE in Intermediate Stage HCC Beyond Up-to-7
Official Title: A Phase III Multicenter Randomized Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria
Acronym: REPLACE
Organization: Translational Research in Oncology
Organization Class: OTHER
Organization Study ID: TRIO041
Secondary IDs
Secondary ID Type Domain Link
EU CT 2022-501969-42-00 OTHER European Medicines Agency EMA None
Start Status Module Data
Status Verified Date: 2024-09
Overall Status: RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Translational Research in Oncology
Lead Sponsor Class: OTHER
Lead Sponsor: Translational Research in Oncology
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload